In listening to Genmab's Jefferies presentation, the point was made at the very end that Genmab's expectation is that the new oral drugs, like PCYC's BTK inhibitor, will be combined with Arzerra down the road, not replace it. The speaker mentioned the different MoA and the potential for synergy when combining.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.